← All trials
NCT02002325
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2014
- Primary completion
- Dec 1, 2019
- Completion date
- Mar 1, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 300
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- National Cerebral and Cardiovascular CenterLead sponsor
- National Cerebral and Cardiovascular CenterOverall official - principal investigator
- Charitable Trust Mihara Cerebrovascular Disorder Research Promotion FundCollaborator
- Japan Agency for Medical Research and DevelopmentCollaborator
- National Cerebral and Cardiovascular CenterReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.